Related Experiment Video

Updated: Aug 14, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

KRAS inhibition in metastatic colorectal cancer: An update

Maliha Nusrat1, Rona Yaeger1

  • 1Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Current Opinion in Pharmacology
|January 13, 2023
PubMed

Insights

Targeting KRAS mutations in colorectal cancer shows promise but faces challenges. Novel KRAS inhibitors demonstrate limited efficacy, necessitating further research into resistance mechanisms and combination therapies for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • KRAS gene mutations are prevalent in approximately 50% of colorectal cancers.
  • These mutations are linked to poorer patient prognosis and historically lacked targeted therapies.

Purpose of the Study:

  • To review clinical strategies for targeting KRAS mutations in colorectal cancer.
  • To discuss novel KRAS inhibitors and their efficacy in clinical trials.
  • To explore resistance mechanisms and potential combination therapies.

Main Methods:

  • Review of clinical studies on KRAS inhibitors (downstream and direct).
  • Analysis of early clinical trial data for KRAS inhibitors in colorectal cancer.
  • Examination of signaling pathways and the tumor-immune microenvironment.

Main Results:

  • Direct KRAS inhibitors show limited activity in colorectal cancer compared to other cancer types.
  • Receptor tyrosine kinase and parallel signaling pathways influence treatment response.
  • KRAS mutations impact the tumor-immune microenvironment, affecting immunotherapy potential.

Conclusions:

  • Targeting KRAS in colorectal cancer requires overcoming resistance mechanisms.
  • Combination strategies involving novel inhibitors and immunotherapy may improve outcomes.
  • Further research is needed to optimize KRAS-targeted therapies for colorectal cancer patients.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.1K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K